Antares Pharma, Inc. (ATRS)

R&D to Revenue

12.05%

Quarterly · Period ending:

ATRS logo

ATRS R&D to Revenue

Latest reported12.05%
ATRS Quarterly R&D/Revenue (0.00% → 12.05%)
High-resolution chart · PNG

ATRS r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Antares Pharma, Inc. R&D to Revenue — Quarterly
Period endingR&D to Revenue
12.0509%
7.9869%
8.1405%
8.9977%
6.2733%
5.2523%
6.012%
7.4636%
9.0118%
7.6112%
8.3455%
8.7715%
10.2508%
9.2822%
20.2093%
25.7732%
26.1356%
25.7277%
21.8533%
23.5489%
25.703%
39.2525%
44.2069%
32.2857%
45.849%
47.8016%
46.3874%
31.6824%
52.4432%
68.2533%
67.372%
62.3215%
87.1483%
63.0236%
80.9762%
78.5189%
71.3161%
102.9076%
68.5989%
54.881%
41.9134%
29.0112%
36.4684%
54.9365%
49.0072%
65.2487%
74.7171%
73.5102%
62.0027%
75.3589%
98.224%
105.0224%
108.9003%
110.6419%
155.0695%
128.8537%
176.4457%
69.0636%
134.2459%
84.2428%
28.9617%
55.8288%
110.0278%
111.675%
135.2463%
59.6386%
207.708%
220.0264%
174.269%
195.5306%
143.4007%
87.3601%
91.4789%
153.5495%
64.0612%
75.6731%
78.5358%
131.1085%
68.4507%
72.0966%
109.2914%
122.0743%
114.9369%
74.4769%
92.2578%
124.3748%
66.5691%
37.6656%
56.5788%
66.2238%
120%
83.3333%
43.75%
460.816%
100%
75%
66.6667%
55.3658%
100%
77.7778%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.